Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) shows significant upside potential with a mean price target of $36.25, indicating a 154.2% increase from the current price of $14.26 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $11.25, suggesting variability in analyst predictions. The lowest estimate is $15.00 (5.2% increase), while the highest is $48.00 (236.6% increase) [2]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MLYS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.6%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]. - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for potential price movement [14].